codeine phosphate + prednisolone + sulphasalazine

This is a combination drug consisting of three active pharmaceutical ingredients:

• Codeine phosphate is an opioid analgesic used for the relief of mild to moderate pain. It acts primarily as a prodrug, being metabolized in the body to morphine, which then exerts its effects by binding to mu-opioid receptors in the central nervous system, resulting in analgesia and cough suppression.
• Prednisolone is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressive properties. It works by binding to glucocorticoid receptors, inhibiting pro-inflammatory gene expression and promoting anti-inflammatory pathways. Prednisolone also inhibits phospholipase A2 activity, reducing arachidonic acid derivatives and suppressing immune cell migration.
• Sulphasalazine (sulfasalazine) is a disease-modifying anti-rheumatic drug (DMARD) used mainly for inflammatory bowel diseases such as ulcerative colitis and Crohn's disease, as well as rheumatoid arthritis. Its mechanism involves inhibition of prostaglandin synthesis (via prostaglandin G/H synthase 1/2), antagonism of phospholipase A2, inhibition of nuclear factor kappa-B signaling pathways, and modulation of immune responses.

This combination may be used together for synergistic management of inflammatory conditions such as ulcerative colitis or Crohn's disease where pain control (codeine), inflammation reduction (prednisolone), and long-term immunomodulation (sulphasalazine) are required. There is no evidence that this specific triple combination exists under a unique brand name; it appears to be prescribed off-label or compounded when clinically indicated.